Standard CXL better at stabilizing progressive keratoconus

Article

Benzalkonium chloride-assisted (BAC) transepithelial collagen crosslinking (CXL) with 0.5% proparacaine drops is less effective than standard CXL in patients with progressive keratoconus

Benzalkonium chloride-assisted (BAC) transepithelial collagen crosslinking (CXL) with 0.5% proparacaine drops is less effective than standard CXL in patients with progressive keratoconus, claims a study in the Journal of Cataract and Refractive Surgery.

The study, headed by Dr Carina Koppen, Department of Ophthalmology, Antwerp University Hospital, Belgium, enrolled 53 eyes of 38 keratoconus patients. The Placido disk device was used to measure sphere, cylinder, as well as maximum keratometry (K max) simulated K values and refractive power values.

Standard CXL was preceded by administration of proparacaine drops 0.5% preserved with BAC 0.005% every five minutes during a thirty minute time period. Results were compared before CXL and post-CXL at 6, 12 and 18 months.

Only corrected distance visual acuity demonstrated a statistically significant improvement at six and twelve months postoperatively. Standard CXL was significantly more effective in stabilizing progressive keratoconus.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.